Alternative profiling platform based on MELDI and its applicability in clinical proteomics
- PMID: 17705703
- DOI: 10.1586/14789450.4.4.447
Alternative profiling platform based on MELDI and its applicability in clinical proteomics
Abstract
The presence of numerous proteomics data and their results in literature reveal the importance and influence of proteins and peptides on human cell cycle. For instance, the proteomic profiling of biological samples, such as serum, plasma or cells, and their organelles, carried out by surface-enhanced laser desorption/ionization mass spectrometry, has led to the discovery of numerous key proteins involved in many biological disease processes. However, questions still remain regarding the reproducibility, bioinformatic artifacts and cross-validations of such experimental set-ups. The authors have developed a material-based approach, termed material-enhanced laser desorption/ionization mass spectrometry (MELDI-MS), to facilitate and improve the robustness of large-scale proteomic experiments. MELDI-MS includes a fully automated protein-profiling platform, from sample preparation and analysis to data processing involving state-of-the-art methods, which can be further improved. Multiplexed protein pattern analysis, based on material morphology, physical characteristics and chemical functionalities provides a multitude of protein patterns and allows prostate cancer samples to be distinguished from non-prostate cancer samples. Furthermore, MELDI-MS enables not only the analysis of protein signatures, but also the identification of potential discriminating peaks via capillary liquid chromatography mass spectrometry. The optimized MELDI approach offers a complete proteomics platform with improved sensitivity, selectivity and short sample preparation times.
Similar articles
-
Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.Rapid Commun Mass Spectrom. 2008;22(3):291-300. doi: 10.1002/rcm.3364. Rapid Commun Mass Spectrom. 2008. PMID: 18181248
-
Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics.J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 15;847(1):30-7. doi: 10.1016/j.jchromb.2006.09.048. Epub 2006 Nov 16. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17112795
-
Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.Clin Cancer Res. 2009 Jun 1;15(11):3812-9. doi: 10.1158/1078-0432.CCR-08-2701. Epub 2009 May 26. Clin Cancer Res. 2009. PMID: 19470732
-
Multidimensional protein identification technology: current status and future prospects.Expert Rev Proteomics. 2005 Jan;2(1):27-39. doi: 10.1586/14789450.2.1.27. Expert Rev Proteomics. 2005. PMID: 15966850 Review.
-
Discovery of regulatory molecular events and biomarkers using 2D capillary chromatography and mass spectrometry.Expert Rev Proteomics. 2006 Feb;3(1):63-74. doi: 10.1586/14789450.3.1.63. Expert Rev Proteomics. 2006. PMID: 16445351 Review.
Cited by
-
Urinary proteomics as a novel tool for biomarker discovery in kidney diseases.J Zhejiang Univ Sci B. 2010 Apr;11(4):227-37. doi: 10.1631/jzus.B0900327. J Zhejiang Univ Sci B. 2010. PMID: 20349519 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources